Case Reports in Hematology / 2013 / Article / Fig 2

Case Report

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan

Figure 2

Chest X-ray (a) and CT scan ((b) and (c)) immediately before the administration of yttrium-90 ibritumomab tiuxetan. Chest X-ray (d) and CT ((e) and (f)) 2 months after its administration. Chest X-ray (g) and CT scan ((h) and (i)) 18 months after its administration. The abnormal shadow was significantly reduced after the administration of yttrium-90 ibritumomab tiuxetan. Radiation pneumonitis has not been reported for 18 months.
675187.fig.002a
(a)
675187.fig.002b
(b)
675187.fig.002c
(c)
675187.fig.002d
(d)
675187.fig.002e
(e)
675187.fig.002f
(f)
675187.fig.002g
(g)
675187.fig.002h
(h)
675187.fig.002i
(i)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.